Adagen, an enzyme replacement treatment for adenosine deaminase deficiency, was the first protein-polymer conjugate to be approved in early 1990 s. Post this regulatory approval …
RRS Thakur, HL McMillan, DS Jones - Journal of Controlled Release, 2014 - Elsevier
In situ forming (ISF) drug delivery implants have gained tremendous levels of interest over the last few decades. This is due to their wide range of biomedical applications such as in …
Nanocarriers passively accumulate in solid tumors through irregular wide fenestrations in neovasculature and increased retention due to poor lymphatic drainage, a phenomenon …
F Canal, J Sanchis, MJ Vicent - Current opinion in biotechnology, 2011 - Elsevier
Polymer Therapeutics have enormously evolved in the past decades. Several polymeric drugs as well as polymer–protein conjugates have been in the market since the 90s, but …
A Besheer, G Hause, J Kressler, K Mäder - Biomacromolecules, 2007 - ACS Publications
Hydroxyethyl starch (HES) is a water soluble semisynthetic polysaccharide that is used as a plasma volume expander and cryoprotectant. In order to produce a fully biodegradable …
A Abdalla, K Mäder - European journal of pharmaceutics and …, 2007 - Elsevier
The purpose of the current study is to investigate the feasibility of producing solid self- emulsifying pellets using the extrusion/spheronization technique. Pellets were made from a …
Nanoparticles (NPs) are promising carriers for dermal and transdermal drug delivery. However, the underlying dynamics of drug release from the NPs, especially, how the …
Y Li, MS Budamagunta, J Luo, W Xiao, JC Voss… - ACS …, 2012 - ACS Publications
Fully understanding the influence of blood proteins on the assembly structure and dynamics within nanoparticles is difficult because of the complexity of the system and the difficulty in …
From Ringsdorf's model to the clinic: current status of polymer-drug conjugates 2.1. Polymer conjugates carrying orthodox anticancer agents 2.1. 1. Polymer-Dox conjugates 2.1. 2 …